Niels Ryberg Finsen: Father of Phototherapy and Pioneer of Lupus Vulgaris Treatment (1903)

Nobel Information Card

• Award Year: 1903
• Field: Physiology or Medicine
• Award Rationale: For his contributions to the treatment of diseases — especially lupus vulgaris — with concentrated light radiation, opening a new path for medical science.
• Born: 15 December 1860, Tórshavn, Faroe Islands
• Died: 24 September 1904, Copenhagen, Denmark
• Nationality: Danish
• Institution: Finsen Medical Light Institute, Copenhagen

Life and Education

Niels Ryberg Finsen was born on 15 December 1860 in Tórshavn, the capital of the Faroe Islands. His father, Hannes Steingrim Finsen, was a respected civil servant of Icelandic descent serving in the Faroe Islands. His mother, Johanne Fromann, came from a Danish family. The Finsens were one of the leading intellectual families of Iceland and the Faroe Islands.

The harsh climate and limited sunshine of the Faroe Islands deeply shaped Finsen's childhood. In this small archipelago of the North Atlantic, sunny days were rare and precious. This experience may have played an important role in his later focus on the biological effects of light. After his early education in the Faroe Islands, Finsen was sent to Denmark at the age of fourteen.

After completing secondary school at Herlufsholm Kostskole and then in Reykjavík, Finsen enrolled at the University of Copenhagen Faculty of Medicine in 1882. During his medical studies he served as an anatomy prosector and began investigating the effects of light on animal tissue. He received his medical degree in 1890 but, rather than opening a practice, turned to a career in research.

Finsen's personal health had a profound effect on his scientific work. From a young age he suffered from a progressive illness now thought to be a form of Niemann-Pick disease. It was characterised by enlargement of the liver and spleen, fluid retention and growing weakness. As the disease progressed his mobility declined, and in the last years of his career he was confined to a wheelchair. Yet despite these severe conditions he showed extraordinary productivity and determination.

Scientific Work

Finsen's scientific curiosity grew out of the effects of sunlight on living organisms. In his first major paper, published in 1893, he showed that the red and ultraviolet components of sunlight have different biological effects. The work was one of the pioneering studies that laid the foundations of photobiology.

Finsen used a simple but effective approach in his experiments. By exposing amphibian larvae and insects to light of different wavelengths, he systematically studied light's effect on living tissue. He discovered that red light was harmless while ultraviolet light produced marked biological effects on tissue.

In 1893 Finsen proposed red-light therapy for smallpox (variola). He argued that treating smallpox patients in rooms illuminated with red light reduced the disease's rate of scarring. The approach was based on the hypothesis that ultraviolet light triggered the inflammatory process and that red filters blocked these harmful rays. This treatment was widely adopted in Denmark and Scandinavia.

Finsen's most important work, however, was the use of concentrated light in the treatment of lupus vulgaris. Lupus vulgaris is a form of cutaneous tuberculosis caused by Mycobacterium tuberculosis; in the late 19th century it was a common, disfiguring disease of the face and throat that led to social isolation. Existing treatments were inadequate — surgical excision and cauterisation with caustic agents were painful and usually unsuccessful.

The Discovery That Led to the Nobel Prize

Starting from the bactericidal (bacteria-killing) effect of light, Finsen reasoned that concentrated light could destroy the bacilli in cutaneous tuberculosis lesions. To test this hypothesis he developed a special device — the Finsen lamp. It collected light from a carbon arc lamp, or alternatively sunlight, through large lenses and focused concentrated ultraviolet light directly onto skin lesions.

The technical design of the Finsen lamp was remarkable. Rays from the light source passed through water-filled crystal lenses, which both concentrated the beam and filtered out infrared (heat) rays. The patient's skin could therefore be exposed to intense ultraviolet radiation without being burned. During treatment a glass prism was pressed directly against the lesion to push blood away from the treatment area, allowing the light to penetrate deeper into the tissue.

The first clinical trials began in Copenhagen in 1895. Finsen administered concentrated-light therapy to lupus vulgaris patients in daily sessions. Each session lasted about one to two hours and treatment continued for weeks or even months. The results were striking: lesions that had resisted treatment for years began to regress, and many patients were completely cured.

In 1896 Finsen founded the Finsen Medical Light Institute to expand his work. The institute was financed by the Danish government and by philanthropists. Hundreds of lupus vulgaris patients were treated there and the results were meticulously recorded. Analysing the data from the first 800 patients, Finsen reported complete cure in about 50 percent and marked improvement in 98 percent of cases.

The scientific basis of Finsen's approach rested on several mechanisms. First, the direct bactericidal action of ultraviolet light, which killed tuberculosis bacilli on exposure. Second, light's stimulant effect on tissue: blood flow in the treated area increased and the local immune response was strengthened. Third, photochemical effects: ultraviolet light triggered chemical reactions in cells that accelerated healing.

Finsen's work made a major impact on the international medical community. Light-therapy institutes were established in many European countries and in the United States. The Finsen lamp became one of the most advanced medical technologies of its time, produced commercially and distributed worldwide.

The Prize and After

The 1903 Nobel Prize in Physiology or Medicine was awarded to Niels Ryberg Finsen. The Nobel Committee cited his contributions to the use of concentrated light radiation in the treatment of disease and the new path he opened for medical science. Finsen received the news with great joy, but his health had deteriorated so severely that he could not travel to Stockholm.

By the time of the Nobel Prize Finsen's illness was far advanced. Because of excessive fluid accumulation in the abdomen he had to undergo regular paracentesis (fluid drainage). He could no longer walk and conducted his work from a wheelchair. Despite these severe conditions he continued to direct research at his institute and to develop new treatment protocols.

Just one year after the Nobel Prize, Finsen died in Copenhagen on 24 September 1904. The scientist, who passed away at the age of forty-three, had packed extraordinary achievement into his short life. His death led to national mourning in Denmark and his funeral was held as a state ceremony.

After Finsen's death the Finsen Medical Light Institute carried on his legacy. The institute remained the centre of phototherapy research in the first half of the 20th century and treated thousands of lupus vulgaris patients. Through various transformations it preserved its place within the Danish health system.

Legacy and Impact Today

Niels Finsen is regarded as the founder of modern phototherapy. As the first scientist to put the medical use of light on an experimental and clinical footing, he is the forerunner of phototherapy techniques used today in dermatology, oncology, psychiatry and other fields.

Today phototherapy is a standard treatment for many skin diseases. Psoriasis, vitiligo, eczema and some cutaneous lymphomas can be successfully controlled with ultraviolet light therapy. PUVA (psoralen + UVA) and narrow-band UVB therapies are modern extensions of Finsen's pioneering work.

Photodynamic therapy (PDT) represents one of the most advanced points of Finsen's legacy. In this method light-sensitive drugs are administered to the body and then activated by light of a specific wavelength, selectively destroying cancer cells. Used in skin, oesophageal and bladder cancers, PDT is a modern reflection of Finsen's vision for the medical use of light.

Light therapy for seasonal affective disorder (SAD) is also indirectly linked to Finsen's legacy. The discovery that depressive symptoms appearing as sunlight declines in winter can be eased by bright light therapy is another sign of light's broad effects on human physiology.

Phototherapy for neonatal jaundice (neonatal hyperbilirubinemia) has saved the lives of millions of babies. The principle that blue light breaks down bilirubin is one of the most widespread clinical applications of the scientific tradition that began with Finsen's founding of photobiology.

Lesser-Known Facts

• When Finsen received the Nobel Prize he was so ill that he could not travel to Stockholm; the award was delivered to him in Copenhagen. He died just one year after receiving the prize.
• Growing up in the Faroe Islands meant he had experienced the scarcity of sunlight firsthand. This personal experience is thought to have sparked his curiosity about the biological effects of light.
• Finsen's illness was probably Niemann-Pick disease type C, a rare genetic disorder affecting the liver, spleen and nervous system. Despite his illness he continued to work with great determination.
• The Finsen lamp was one of the most expensive medical devices of its era. The first Finsen lamps used sunlight, so treatment depended on sunny days; electric arc lamps later removed this dependency.
• Copenhagen's Finsen Institute drew patients from all over the world in the early 20th century, with wealthy British and American patients in particular travelling to Denmark for treatment.
• In his last years Finsen also studied the health effects of seawater baths and salt use, but he died before completing this work.
• Scientific events in his memory are still held in Denmark, and the Finsen Medal remains a prestigious award for outstanding achievement in dermatology.